

News Release

STOCK EXCHANGE LISTINGS: NEW ZEALAND (FPH), AUSTRALIA (FPH)

Record half year result for Fisher & Paykel Healthcare: net profit up 86%

Auckland, New Zealand, 25 November 2020 - Fisher & Paykel Healthcare Corporation Limited today announced its results for the first half of the 2021 financial year, which ended 30 September 2020. Net profit after tax was \$225.5 million, up 86% over the same period in the previous financial year, or 87% in constant currency. Operating revenue was \$910.2 million, up 59% or 61% in constant currency.

"I would like to express our thanks and admiration for the healthcare providers around the world, who have responded with care and courage to the COVID-19 pandemic. I also want to thank everyone across our entire business, as well as their partners and families, for their contribution to ensuring those healthcare providers have the equipment they need to care for their patients," said Managing Director and CEO Lewis Gradon. "Our thanks and gratitude also extend to our suppliers around the world. They have gone above and beyond to answer the global call for our products."

The strong result was driven by the increased demand for the company's Hospital hardware, in particular its Optiflow™ and Airvo™ systems. This reflected a shift in clinical practice toward using nasal high flow therapy as a front-line treatment for COVID-19 patients in hospital.

In the Hospital product group, which includes products used in acute and chronic respiratory care and surgery, operating revenue grew 93% over the first half of the previous financial year to \$681.0 million, or 94% growth in constant currency. Hospital products made up three-quarters of the company's operating revenue.

"Sales in hardware and consumables continued to track surges in COVID-19 globally, as the virus moved across Europe, North America, South America and South Asia," said Gradon.

In the Homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and nasal high flow therapy in the home, operating revenue grew 5% to \$226.2 million, or 6% growth in constant currency.

"Since the pandemic started, many sleep clinics have been closed, resulting in a reduction in new patient diagnoses. Our F&P Evora™ and F&P Vitera™ masks for OSA are great products that have yet to reach their full potential," said Gradon.

A reduction in gross margin for the six-month period to 61.7% was due to the increased use of air freight and the elevated costs associated with it. Excluding these additional freight costs, gross margin was in line with the first half of the previous financial year in constant currency.

The company's directors have approved an interim dividend of 16 cents per ordinary share, an increase of 33% on the interim dividend last year. The interim dividend, carrying full New Zealand imputation credit, will be paid on 16 December 2020 with a record date of 4 December 2020.

Guide for the remainder of FY2021

"We had a strong first half of the year and have continued to expand our installed base of hardware in hospitals," said Gradon. "Since our last trading update in August, we maintained the same level of both hardware and consumables revenue in our Hospital product group for the half year. In our Homecare product group, OSA masks revenue also continued at similar levels to the first four months of the financial year."

We cannot predict the course of COVID-19, the effectiveness or adoption of preventative measures, the progress of a vaccine and its outcomes, the impact on future hospitalisation rates, or the

investments countries may make in treatment measures. Consequently, we have no basis on which to provide guidance for the full 2021 financial year, so we are providing a guide to full-year results based on the following assumptions:

- Hospital hardware sales return to normal levels from January 2021.
- The use of our hospital hardware returns down to approximately normal rates for the second half of the financial year.
- OSA diagnosis rates are reduced for the second half of the financial year, due to limited access to customers.
- Freight costs remain elevated, resulting in a reduction in gross margin of approximately 200 bps in constant currency for the full financial year compared to the prior financial year.

Based on these assumptions, and reflecting sustained stronger Hospital hardware sales to date, full year operating revenue would be approximately \$1.72 billion, and net profit after tax would be approximately \$400 million to \$415 million. This guide is based on exchange rates of NZD:USD 0.69 and NZD:EUR 0.58.

Our assumptions used in providing this guide are not a prediction of the course of COVID-19 around the world and do not impact our production planning. We will continue to accelerate our investment in manufacturing capacity to ensure that a further increase in supply of our products is available,” said Gradon.

“Our heartfelt thanks go out to our customers and to our suppliers, shareholders and clinical partners who are supporting us during this extraordinary year,” he concluded.

Overview of key results for the first half

- 86% growth in net profit after tax to a record \$225.5 million (1H FY20: \$121.2 million).
- 59% growth in operating revenue to \$910.2 million, 61% growth in constant currency.
- 93% growth in Hospital operating revenue to \$681.0 million, 94% growth in constant currency.
- 43% constant currency revenue growth for new applications consumables; i.e. products used in non-invasive ventilation, Optiflow nasal high flow therapy and surgical applications, accounting for 63% of Hospital consumables revenue.
- 5% growth in Homecare operating revenue, 6% growth in constant currency.
- 3% growth in constant currency revenue in OSA masks.
- Investment in R&D was 7% of revenue, or \$64.6 million.
- 33% increase in interim dividend to 16 cps (1H FY20: 12 cps).

About Fisher & Paykel Healthcare

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea. The company's products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Ends

Media & Investor Contacts:

Karen Knott
Senior Communications Manager
karen.knott@fphcare.co.nz
+64 21 713 911

Hayden Brown
Investor Relations Manager
hayden.brown@fphcare.co.nz
+64 27 807 8073

Authorised by Fisher & Paykel Healthcare Corporation Limited's Board of Directors.

Accompanying Documents

Attached to this news release are the following additional documents:

- Results in Brief
- Interim Report 2021
- Investor Presentation
- NZX Results Announcement
- NZX Distribution Notice

Constant Currency Information

Constant currency information included within this news release is non-GAAP financial information, as defined by the NZ Financial Markets Authority, and has been provided to assist users of financial information to better understand and track the company's comparative financial performance without the impacts of spot foreign currency fluctuations and hedging results and has been prepared on a consistent basis each year. A constant currency analysis is included on page 15 of the company's Interim Report 2021, and the company's constant currency framework can be found on the company's website at www.fphcare.com/ccf.

Half Year Results Conference Call

Fisher & Paykel Healthcare will host a conference call today to review the results and to discuss the outlook for the remainder of the 2021 financial year. The conference call is scheduled to begin at 10:00am NZDT, 8:00am AEDT Wednesday 25 November (4:00pm USEST, Tuesday 24 November) and will be broadcast simultaneously over the Internet.

To listen to the webcast, access the company's website at www.fphcare.com/investor. An online archive of the event will be available approximately two hours after the webcast and will remain on the site for two weeks.

To attend the conference call, participants should dial in to one of the numbers below at least five minutes prior to the scheduled call time and identify yourself to the operator. When prompted, please quote the conference code of: **950349**.

New Zealand	+64 9 913 3624	US/Canada	+1 646 828 8195
Australia	+61 2 9193 3719	Hong Kong	+852 3008 1529
United Kingdom	+44 330 336 9104	International	+64 9 913 3624

Results in Brief

	Six Months Ended 30 Sep 19 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 20 NZ\$M (except as otherwise stated)	% Change (Reported)	% Change (Constant Currency ¹)
FINANCIAL PERFORMANCE				
Total operating revenue	570.9	910.2	+59%	+61%
Cost of sales	(188.0)	(348.3)	+85%	+81%
Gross profit	382.9	561.9	+47%	+51%
Gross margin	67.1%	61.7%	-534bps	-420bps
Selling, general and administrative expenses	(162.9)	(188.1)	+15%	+16%
Research and development expenses	(54.0)	(64.6)	+20%	+20%
R&D percentage of operating revenue	9.5%	7.1%	-236bps	
Total operating expenses	(216.9)	(252.7)	+17%	+17%
Operating profit before financing costs	166.0	309.2	+86%	+95%
Operating margin	29.1%	34.0%	+489bps	+610bps
Net financing (expense)	(6.3)	3.8	-160%	
Profit before tax	159.7	313.0	+96%	+94%
Tax expense	(38.5)	(87.5)	+127%	+117%
Profit after tax	121.2	225.5	+86%	+87%
Effective tax rate	24.1%	28.0%		
Effective tax rate excluding R&D tax credit	28.2%	30.0%		

Revenue by Region:

North America	259.6	373.9	+44%
Europe	158.3	269.9	+70%
Asia Pacific	126.5	184.4	+46%
Other	26.5	82.0	+209%
Total	570.9	910.2	+59%

Revenue by Product Group:

Hospital	353.6	681.0	+93%
Homecare	214.7	226.2	+5%
Core products sub-total	568.3	907.2	+60%
Distributed and other	2.6	3.0	+15%
Total	570.9	910.2	+59%

	As at 31 March 20 NZ\$M (except as otherwise stated)	As at 30 Sep 20 NZ\$M (except as otherwise stated)	
FINANCIAL POSITION			
Tangible assets	1,270.4	1,486.2	+17%
Intangible assets	164.6	145.5	-12%
Total assets	1,435.0	1,631.7	+14%
Total liabilities	(461.2)	(408.6)	-11%
Shareholders' equity	973.8	1,223.1	+26%
Gearing	(4.3%)	(7.1%)	-285bps
Net tangible asset backing (cents per share)	141	187	+33%

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any impact from changes in foreign exchange rates. The company's constant currency framework can be found on the company's website at www.fphcare.com/ccf. The reconciliation to reported results is included within the Financial Commentary section of the Interim Report.

² Includes Intangible and deferred tax assets.

For personal use only


Results in Brief (continued)

	Six Months Ended 30 Sep 19 NZ\$M (except as otherwise stated)	Six Months Ended 30 Sep 20 NZ\$M (except as otherwise stated)	% Change
CASH FLOWS			
Net cash flow from operating activities	113.5	218.1	+92%
Net cash flow (used in) investing activities	(39.1)	(81.9)	+109%
Net cash flow (used in) financing activities	(80.6)	(92.9)	+15%
SHARES OUTSTANDING			
Weighted average basic shares outstanding	573,908,740	574,981,039	
Weighted average diluted shares outstanding	578,703,191	579,449,729	
Basic shares outstanding at period end	574,244,939	576,123,608	
DIVIDENDS AND EARNINGS PER SHARE			
Dividends per share (cents) – declared	12.0	16.0	+33%
Basic earnings per share (cents)	21.1	39.2	+86%

For personal use only







Contents

HALF YEAR FINANCIAL HIGHLIGHTS	4
HALF YEAR BUSINESS UPDATES	5
PRODUCT GROUP OVERVIEW	6
HALF YEAR REVIEW	8
FINANCIAL COMMENTARY	12
FINANCIAL STATEMENTS	16
NOTES TO THE FINANCIAL STATEMENTS	20
DIRECTORY	25

Constant currency information contained within this report is non-conforming financial information, as defined by the NZ FMA and has been provided to assist users of financial information to better understand and assess the company's financial performance without the impacts of spot financial currency fluctuations and hedging results, and has been prepared on a consistent basis each financial year. A reconciliation between reported results and constant currency results is available on page 15 of this report. The company's constant currency framework can be found on our website at www.fphcare.com/ccf.

This report is dated 24 November 2020 and is signed on behalf of Fisher & Paykel Healthcare Corporation Limited by Scott St John, Chairman and Lewis Gradon, Managing Director and Chief Executive Officer.



SCOTT ST JOHN, CHAIRMAN



LEWIS GRADON, MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

ADAPTING AT PACE

Guided by a strong sense of purpose, we have adapted at pace to answer the global call. **ACCELERATING** the production of devices and systems that help patients breathe. **MAINTAINING** strong connections between our customers, distribution partners and sales representatives. **DEVELOPING** resources to maximise the impact of the life-sustaining products we design and manufacture. It's all about **CARING**, and it's what we do.

Half year financial highlights

OPERATING REVENUE

\$910.2M

▲ 59% | 1H FY20 \$570.9M

NET PROFIT AFTER TAX

\$225.5M

▲ 86% | 1H FY20 \$121.2M

GROSS MARGIN

61.7%

INTERIM DIVIDEND
FULLY IMPUTED

16CPS

▲ 33% | 1H FY20 12CPS

SPEND ON R&D

\$64.6M

7% OF OPERATING REVENUE

HOSPITAL REVENUE

\$681.0M

▲ 93% | 1H FY20 \$353.6M

HOSPITAL HARDWARE
REVENUE GROWTH

↑383%

(CONSTANT CURRENCY)


NEW APPLICATIONS CONSUMABLES
REVENUE GROWTH

↑43%



(CONSTANT CURRENCY)

Half year business updates

REVENUE BY REGION 6 MONTHS TO 30 SEPTEMBER 2020



REVENUE BY PRODUCT GROUP 6 MONTHS TO 30 SEPTEMBER 2020



+ CONTRIBUTED

to the global fight against COVID-19 by increasing manufacturing production on some hospital hardware devices by more than six times.

+ APPOINTED

Scott St John as chair of the Board, replacing director Tony Carter, who retired in August.

+ DEVELOPED

a new education website to provide training and support to clinicians treating patients with COVID-19.

+ LAUNCHED

F&P Evora™ compact nasal mask in the US, and a patient mask app in the US, Canada, Australia and UK.

+ PRESENTED

a virtual Nasal High Flow/ COVID-19 symposium for 900 attendees at the European Respiratory Society Congress 2020.

+ ACCELERATED

the installation of production lines in the Daniell Building, our fourth manufacturing facility in New Zealand.

+ COMMENCED

planning for a third manufacturing facility in Mexico to be completed in financial year 2023.

Product group overview

Our business is structured in two parts: Hospital and Homecare.

Hospital

Our Hospital product group includes products used in invasive ventilation, non-invasive ventilation, nasal high flow therapy, and laparoscopic and open surgery. Not only do these products help healthcare providers improve patient outcomes, they often deliver economic benefits as well, by reducing the need to escalate care and shortening patient stays in hospital.

75%

OF OPERATING REVENUE

OPERATING REVENUE
1H FY21 \$681.0M

↑93%

CONSTANT CURRENCY REVENUE FROM
NEW APPLICATIONS CONSUMABLES

↑43%

Homecare

The Homecare product group includes devices and systems used to treat obstructive sleep apnea (OSA) and provide respiratory support in the home. These include our CPAP therapy masks as well as flow generators, interfaces, and data management technologies.

25%

OF OPERATING REVENUE

OPERATING REVENUE
1H FY21 \$226.2M

↑ 5%

CONSTANT CURRENCY
REVENUE

↑ 6%

Half year review

We typically begin this letter by reflecting on our achievements over the past six months. As the world continues to grapple with a pandemic, we believe it is more fitting to start by expressing our thanks and admiration for our customers, the healthcare providers who have responded with care and courage.

We would also like to thank our own teams across the business for their contributions to ensuring that healthcare providers have the equipment they need to care for patients. Lifting production on our most-needed products has required an extraordinary effort from our people, as well as their partners and family members.

Moreover, we would like to thank our suppliers for going above and beyond to provide the raw materials, components and services required to answer the global call for our products.

For the first six months of the 2021 financial year, we are reporting strong financial performance. Operating revenue was

\$910.2 million, up 59 per cent over the previous financial year, or 61 per cent in constant currency. Net profit after tax was \$225.5 million, up 86 per cent, or 87 per cent in constant currency.

Growth continued to be driven by hospital hardware and consumables sales, most notably strong demand for our Optiflow and Airvo systems used for treating COVID-19 patients. This reflected a worldwide change in clinical practice. Informed by emerging studies and anecdotal evidence, respiratory specialists began leading with nasal high flow therapy before resorting to ventilators.

In our Hospital product group, revenue was \$681.0 million, which was a 93 per cent increase over the first half of the 2020 financial year, or 94 per cent in constant currency. Sales in hardware and consumables tracked the surges in COVID-19 globally, as the virus swept across Europe, North America, South America and South Asia.

In our Homecare product group, revenue for the first half was \$226.2 million, which was a 5 per cent increase over the first half of the 2020 financial year, or 6 per cent in constant currency. The first half was challenging for our sales team in obstructive sleep apnea products. Many sleep clinics were closed,



SCOTT ST JOHN
Chairman



LEWIS GRADON
Managing Director
and Chief Executive Officer

We are grateful to our people for responding to the global call with such commitment and dedication.

SCOTT ST JOHN
Chairman

resulting in a reduction in new patient diagnoses. Customers have responded positively to our F&P Evora™ and F&P Vitera™ masks for OSA, and we are confident these are great products that have yet to reach their full potential.

Throughout the pandemic, we have adapted to changing conditions and emerging challenges. We continue to put health and safety first, requiring the use of masks throughout our New Zealand and Mexico facilities and maintaining social distancing protocols.

Face-to-face meetings with customers have been limited, so we are using virtual tools to support our hospital customers, sleep clinics and distribution partners. Our sales representatives have been partnering with clinicians to host educational webinars, and our in-house product and clinical specialists have launched a website to provide urgently needed training and resources.

Key opinion leaders have become outspoken advocates for our products and therapies. One of our long-time collaborators, Dr Gerard Criner from Temple University, contributed to an important study (published in May) on using nasal high flow therapy to treat COVID-19 patients. The benefits of nasal high flow therapy are now mentioned daily in the media. The exposure clinicians have had

to our hardware bodes well for treating respiratory patients in hospitals for the long term.

New products and markets

While significantly increasing production on our humidification systems and products for nasal high flow therapy, we have continued to innovate and release products into new markets. We launched the F&P Nivairo™+ mask for noninvasive ventilation into several Asian countries and our vented Nivairo mask into the US. We also released our Optiflow 3S interface in the US. For patients using nasal high flow therapy in the home, we launched new myAirvo tube and chamber kits for adults and children, and home versions of Optiflow Junior interfaces for infants in Europe, Canada and Australia.

Facilities

We continue to plan ahead for our facilities needs and expand our manufacturing capacity. When COVID-19 restrictions were eased, we accelerated the opening of the Daniell Building, our fourth building in New Zealand. In addition to housing some of our research and development teams, the new space expands our manufacturing and distribution space, so we can rebuild stock to pre-COVID-19 inventory levels.

We have commenced planning on our third manufacturing facility in Tijuana, Mexico, and we expect it to be ready for occupancy in the 2023 financial year.

Dividend

The Board of Directors has approved a fully imputed interim dividend of 16 cents per share for the six months to 30 September 2020, which is an increase of 33 per cent on the first half of the prior year. The dividend will be paid on 16 December 2020.

Board and management

Director Scott St John took the helm as chair of the Board following Tony Carter's retirement in August, and Neville Mitchell was appointed chair of the Audit & Risk Committee.

On our executive management team, Nicola Talbot has been appointed VP Human Resources following Debra Lumsden's departure to pursue other opportunities. Nicola has more than 20 years of experience with Fisher & Paykel Healthcare. She has been involved in establishing our global offices, recruiting, developing and supporting our people in 39 countries.

An extraordinary effort

We believe it's important to recognise and reward our people across the company. Consistent with this belief, the Board has approved a profit-sharing bonus totalling \$12 million to everyone who has worked with us for a qualifying period.

As always, we are grateful to our shareholders for supporting us during this extraordinary year. At a time in history that defies expectations, we are still doing what we do best – designing, manufacturing and delivering products that improve care and outcomes for patients. Whatever the future holds, we will keep adapting at pace.



SCOTT ST JOHN
CHAIRMAN



LEWIS GRADON
MANAGING DIRECTOR AND CHIEF EXECUTIVE OFFICER

personal use only

Financial report

Financial commentary

INCOME STATEMENTS

For the six months ended 30 September	2019 NZ\$M	2020 NZ\$M	Change Reported %	Change CC (1) %
Operating revenue	570.9	910.2	+59	+61
Gross profit	382.9	561.9	+47	+51
Gross margin	67.1%	61.7%	-534 bps	-420 bps
SG&A expenses	(162.9)	(188.1)	+15	+16
R&D expenses	(54.0)	(64.6)	+20	+20
Total operating expenses	(216.9)	(252.7)	+17	+17
Operating profit	166.0	309.2	+86	+95
Operating margin	29.1%	34.0%	489 bps	610 bps
Financing income/(expenses) (net)	(6.3)	3.8	-	-
Profit before tax	159.7	313.0	+96	+94
Taxation	(38.5)	(87.5)	+127	+117
Profit after tax	121.2	225.5	+86	+87

¹ Constant currency (CC) removes the impact of exchange rate movements. This approach is used to assess the Group's underlying comparative financial performance without any distortion from changes in foreign exchange rates. A full reconciliation and basis of preparation is set out on page 15.

Total profit after tax for the period was up 86% to \$225.5 million (87% in constant currency).

Revenue

Operating revenue was \$910.2 million, 59% higher than the same period last year or 61% in constant currency. Hospital revenue grew 94% in constant currency driven by the demand for products used to treat COVID-19 patients. Homecare revenue increased 6% in constant currency.

Gross margin

Gross margin decreased by 420 basis points in constant currency due to additional air freight to expedite deliveries in response to COVID-19. Gross margin excluding additional freight was 65.9%, which was above our long term target of 65% and in line with last year in constant currency.

Operating expenses

Operating expenses increased 17% (17% in constant currency) to \$252.7 million, reflecting ongoing expenditure to support global sales growth and COVID-19 response operating costs. This more than offset lower travel and sales event-related activities in the current period following global COVID-19 travel restrictions.

Research & development (R&D) spend of \$64.6 million grew 20%. Over the long term we expect R&D spend to grow on average in line with constant currency revenue growth.

Financing expenses


Total reported financing expenses decreased to be net income – driven, mainly by the gain on foreign currency interest-bearing liabilities, including lease liabilities. Excluding the impact of foreign currency movements, net financing expense increased by \$0.5M.

Tax

Our effective tax rate for the period was 28.0% up from 24.1% in the prior period. Excluding the benefit from the R&D tax credit, the effective tax rate was 30.0% for the period (2019: 28.2%), reflecting the effect of foreign currency translations. The R&D tax credit reported this year of \$6.4 million (2019: \$6.6 million) represents the estimated eligible R&D expenditure incurred during the period.

FOREIGN CURRENCY IMPACTS

The Group is exposed to movements in foreign exchange rates, with operating revenue generated in a wide range of currencies as shown below.



Approximately 61% of COGS and over 49% of operating expenses are in currencies other than NZD.

The volatility in foreign currency markets which saw the NZD/USD spot rate decline to below 0.60 prior to 31 March 2020 has eased, with the NZD/USD at 0.66 at 30 September 2020. This resulted in significant changes in the valuation of derivatives and other balances denominated in foreign currency, including foreign accounts receivable and foreign currency debt at 30 September 2020 compared to 31 March 2020. The effect of these balance sheet translations for the period decreased operating revenue by \$10.6 million (2019: \$8.5 million increase) and reduced profit after tax by \$3.6 million (2019: \$0.8 million increase). Foreign exchange hedging resulted in a pre-tax loss of \$1.4 million (2019: \$2.8 million loss).

The NZD strengthened over the six-month period from 31 March 2020. Compared to the prior period, both the average daily spot rate and the average conversion exchange rate (i.e. the accounting rate, incorporating the effect of foreign currency hedging in respect of the relevant financial period) decreased as set out in the table below.

Average daily spot and conversion rates for the period ended 30 September

Period ended 30 September	Average daily spot rate		Average conversion exchange rate	
	2019	2020	2019	2020
USD	0.6556	0.6403	0.6700	0.6551
EUR	0.5866	0.5639	0.5859	0.5559

Foreign exchange hedging position

The hedging position for our main currency exposures as at 13 November 2020 is:

Year to 31 March	2021	2022	2023	2024	2025	2026-27
USD % cover of expected exposure	95%	75%	40%	30%	30%	0%
USD average rate of cover	0.654	0.658	0.637	0.630	0.624	-
EUR % cover of expected exposure	95%	70%	55%	35%	35%	5%
EUR average rate of cover	0.554	0.538	0.521	0.509	0.502	0.470

Hedging cover has been rounded to the nearest 5%.

CASH FLOWS

The full statement of cash flows is provided on page 19.

	2019 NZ\$M	2020 NZ\$M	Change NZ\$M
For the six months ended 30 September			
Operating profit before financing costs	166.0	309.2	143.2
Plus depreciation and amortisation (including leased assets)	28.5	37.0	8.5
Change in working capital and other	(21.2)	(45.5)	(24.3)
Net interest paid (including lease liabilities)	(1.7)	(1.9)	(0.2)
Net income tax paid	(58.1)	(80.7)	(22.6)
Operating cash flows	113.5	218.1	104.6
Lease repayments*	(4.3)	(5.3)	(1.0)
Purchase of land and buildings	(43.0)	(13.5)	29.5
Purchase of plant and equipment	(30.4)	(64.9)	(34.5)
Purchase of intangible assets	(13.2)	(16.1)	(2.9)
Free cash flows	22.6	118.3	95.7
Dividends paid	(77.5)	(89.1)	(11.6)

+ Free cash flows includes lease liability repayments following the adoption of NZ IFRS 16.

Operating cash flows

Cash flows from operations for the period increased 92% to \$218.1 million. Working capital was impacted by a significant increase in receivables from higher sales and higher inventory levels.

Capital expenditure

Property, plant and equipment purchases for the period were \$78.4 million, an increase from \$5.0 million from the prior period. Purchases this year primarily related to production tooling and equipment costs and finalisation of building projects in New Zealand.

BALANCE SHEET

	31 March 2020 NZ\$M	30 September 2020 NZ\$M	Change NZ\$M
As at			
Trade receivables	192.9	210.1	17.2
Inventories	146.5	233.6	87.1
Less trade and other payables*	(108.5)	(113.7)	(5.2)
Working capital	230.9	330.0	99.1
Property, plant and equipment**	735.3	777.0	41.7
Intangible assets	73.9	78.9	5.0
Other net assets/(liabilities)	(74.9)	(11.3)	63.6
Lease liabilities	(33.6)	(29.6)	4.0
Net cash/(debt)	42.2	78.1	35.9
Net assets	973.8	1,223.1	249.3

* Trade and other payables exclude all non-current payables and all employee entitlements and provisions

** Property, plant and equipment includes lease assets recognised

Our balance sheet remains strong with net cash of \$78.1 million.

Trade receivables have increased largely due to strong sales, offset by unfavourable foreign currency translation movements. Our debtors days are 44 days, a slight improvement from 45 days in the prior period. Higher inventories reflect a buildup in raw materials to enable us to meet potential heightened demand and increased finished goods following lower levels in March 2020.

The increase in property, plant and equipment includes recognition of capital investment of \$78.4 million of which \$64.9 million related to production tooling and equipment costs. These increases are offset by \$28.0 million of depreciation.

Construction work on the Daniell Building (our fourth building) was completed in June 2020 on our Auckland, New Zealand campus. Total spend on this project was \$146 million.

Intangible assets have increased by \$5.0 million including patent acquisition costs and ERP implementation costs.

Other net assets/liabilities movements included a significant increase in net derivative instrument assets of \$147.2 million, partially offset by the associated deferred tax movements of \$41.2 million. The NZD accelerated decline as the last financial year ended has now largely reversed. This resulted in the majority of currency derivatives that were in a liability position as at 31 March 2020 to now be in an asset position at 30 September 2020. All currency derivatives continued to be effective hedges. Other movements in net asset/liabilities include an increase in employee-related obligations and taxation payable.

Funding and short-term investments

As at	31 March 2020 NZ\$M	30 September 2020 NZ\$M	Change NZ\$M
Loans and borrowings			
– Current	(49.9)	(45.5)	4.4
– Non-current	(22.0)	(20.7)	1.3
Bank overdrafts	(30.7)	(14.0)	16.7
Total interest-bearing liabilities	(102.6)	(80.2)	22.4
Cash and cash equivalents	67.1	93.2	26.1
Short-term investments	77.7	65.1	(12.6)
Total cash and investments	144.8	158.3	13.5
Net cash (debt)	42.2	78.1	35.9
Gearing	-4.3%	-7.1%	-2.9%
Undrawn debt facilities	148.0	149.3	1.3

The average maturity of loans and borrowings of \$66.2 million at 30 September 2020 was 0.8 years and the currency split was 92% USD; 5% Australian dollars and 3% Canadian dollars (with no NZD denominated debt). Interest-bearing debt decreased by \$22.4 million including the impact of favourable currency revaluations.

Current loans and borrowings included a US\$30 million facility which expired on 1 November 2020 and has been replaced with two new NZ\$30 million multi-currency facilities commencing 14 October 2020 and expiring 30 September 2025.

We held cash balances and short-term investments, mainly in NZD, of \$158.3 million at the end of the period. This balance, and operating cash generated in the second half of FY2021, will fund the payment of the interim dividend, provisional tax and ongoing payments for capital expenditure.

Gearing¹

At 30 September 2020 the group had net cash of \$78.1 million and gearing of -7.1%. Gearing is outside the lower band of the target range of -5% to +5%. Gearing will return to the target range post the dividend payment in December and is projected to remain within the target range for the balance of the financial year.

NOTES – CONSTANT CURRENCY

Constant currency analysis is non-Generally Accepted Accounting Practice (GAAP) financial information that is not prepared in accordance with New Zealand Equivalents to International Financial Reporting Standards (NZ IFRS). Constant currency information has been provided to assist users of financial information to better understand and assess the Group's financial performance without the impacts of foreign currency fluctuations, including hedging results.

Constant currency financial information is prepared each month to enable the Board and management to monitor and assess the Group's underlying comparative financial performance without any distortion from changes in foreign exchange rates. Constant currency information is prepared on a consistent basis for reported periods restated into NZD based on "constant" exchange rates, typically the budgeted exchange rates for the current year. This information excludes the impact of movements in foreign exchange rates, hedging results and balance sheet translations.

The Group's constant currency framework can be found on the company's website at www.fphcare.com/ccf. PwC perform assurance procedures over the constant currency information.

RECONCILIATION OF CONSTANT CURRENCY TO REPORTED PROFIT AFTER TAX

	2019 NZ\$M	2020 NZ\$M	Change NZ\$M
For the six months ended 30 September			
Profit after tax (constant currency)	125.4	234.6	109.2
Spot exchange rate effect	(3.0)	(4.5)	(1.5)
Foreign exchange hedging result	(2.0)	(1.0)	1.0
Balance sheet revaluation	0.8	(3.6)	(4.4)
Profit after tax (reported)	121.2	225.5	104.3

The significant exchange rates used in the constant currency analysis, being the budget exchange rates for the year ending 31 March 2021, are USD 0.64, EUR 0.57, AUD 0.96, GBP 0.49, CAD 0.84, JPY 69 and MXN 12.30.

1. Net interest-bearing debt (debt less cash and cash equivalents and short-term investments) to net interest-bearing debt and equity (less hedging reserves). Net debt excludes all lease liabilities recognised on the adoption of IFRS 16 – Leases.

Financial statements

CONSOLIDATED INCOME STATEMENT

For the six months ended 30 September 2020

	Notes	Unaudited 2019 NZ\$M	Unaudited 2020 NZ\$M
Operating revenue	3	570.9	910.2
Cost of sales		(188.0)	(348.3)
Gross profit		382.9	561.9
Selling, general and administrative expenses		(162.9)	(188.1)
Research and development expenses		(54.0)	(64.6)
Total operating expenses		(216.9)	(252.7)
Operating profit before financing costs		166.0	309.2
Financing income		1.3	0.9
Financing expense		(1.9)	(2.4)
Exchange gain/(loss) on foreign currency interest-bearing liabilities		(5.7)	5.3
Net financing expense		(6.3)	3.8
Profit before tax	4	159.7	313.0
Tax expense		(38.5)	(87.5)
Profit after tax		121.2	225.5
Basic earnings per share		21.1 cps	39.2 cps
Diluted earnings per share		20.9 cps	38.9 cps

The accompanying Notes form an integral part of the Financial Statements.

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the six months ended 30 September 2020

	Unaudited 2019 NZ\$M	Unaudited 2020 NZ\$M
Profit after tax	121.2	225.5
Other comprehensive income		
<i>Items that may be reclassified to profit or loss</i>		
Foreign currency translation reserve		
Exchange differences on translation of foreign operations	2.2	(4.4)
Hedging reserves		
Changes in fair value in hedging reserves	(50.8)	143.8
Transfers to profit before tax from cash flow hedge reserve	(6.6)	2.3
Tax on above reserve movements	16.1	(40.9)
Other comprehensive income, net of tax	(39.1)	100.8
Total comprehensive income	82.1	326.3

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 September 2020

	Notes	Share capital NZ\$M	Retained earnings NZ\$M	Reserves NZ\$M	Total equity NZ\$M
Balance at 31 March 2019 (audited)		219.2	549.2	144.8	913.2
Adjustment on adoption of NZ IFRS 16 (net of tax)		-	(3.4)	-	(3.4)
Balance at 1 April 2019 (unaudited)		219.2	545.8	144.8	909.8
Total comprehensive income		-	121.2	(39.1)	82.1
Dividends paid	9	-	(77.5)	-	(77.5)
Movement in share based payments reserve		2.2	-	2.1	4.3
Balance at 30 September 2019 (unaudited)		221.4	589.5	107.8	918.7
Balance at 31 March 2020 (audited)		225.4	686.3	62.1	973.8
Total comprehensive income		-	225.5	100.8	326.3
Dividends paid	9	-	(89.1)	-	(89.1)
Issue of share capital under employee share plans		18.1	-	-	18.1
Movement in treasury shares		1.3	-	-	1.3
Movement in share based payments reserve		-	-	(7.3)	(7.3)
Balance at 30 September 2020 (unaudited)		244.8	822.7	155.6	1,223.1

The accompanying Notes form an integral part of the Financial Statements.

CONSOLIDATED BALANCE SHEET

As at 30 September 2020

	Notes	Audited 31 March 2020 NZ\$M	Unaudited 30 September 2020 NZ\$M
ASSETS			
Current assets			
Cash and cash equivalents		67.1	93.2
Short-term investments		77.7	65.1
Trade and other receivables		222.7	238.2
Inventories		146.5	233.6
Derivative financial instruments	5	4.1	11.5
Tax receivable		0.6	1.5
Total current assets		518.7	643.1
Non-current assets			
Derivative financial instruments	5	14.1	65.3
Other receivables		2.3	0.8
Property, plant and equipment		735.3	777.0
Intangible assets		73.9	78.9
Deferred tax assets		90.7	66.6
Total assets		1,435.0	1,631.7
LIABILITIES			
Current liabilities			
Interest-bearing liabilities		80.6	59.5
Lease liabilities		11.6	10.3
Trade and other payables		165.6	196.7
Provisions		5.0	7.4
Tax payable		35.4	56.7
Derivative financial instruments	5	36.4	5.5
Total current liabilities		334.6	336.1

	Notes	Audited 31 March 2020 NZ\$M	Unaudited 30 September 2020 NZ\$M
LIABILITIES			
Non-current liabilities			
Interest-bearing liabilities		22.0	20.7
Lease liabilities		22.0	19.3
Provisions		1.5	6.9
Other payables		19.8	22.0
Derivative financial instruments	5	61.3	3.6
Total liabilities		461.2	408.6
EQUITY			
Share capital		225.4	244.8
Retained earnings		686.3	822.7
Reserves		62.1	155.6
Total equity		973.8	1,223.1
Total liabilities and equity		1,435.0	1,631.7

The accompanying Notes form an integral part of the Financial Statements.

On behalf of the Board
24 November 2020

Scott St John
Chairman

Lewis Gradon
Managing Director and Chief Executive Officer

CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 September 2020

	Unaudited 2019 NZ\$M	Unaudited 2020 NZ\$M
CASH FLOWS FROM OPERATING ACTIVITIES		
Receipts from customers	563.8	884.0
Grants received	1.6	–
Interest received	1.6	0.8
Payments to suppliers and employees	(392.1)	(583.3)
Tax paid	(58.1)	(80.7)
Interest paid	(2.4)	(1.9)
Lease interest paid	(0.9)	(0.8)
Net cash flows from operating activities	113.5	218.1
CASH FLOWS FROM INVESTING ACTIVITIES		
Net short-term investments	47.5	12.6
Purchases of property, plant and equipment	(73.4)	(78.4)
Purchases of intangible assets	(13.2)	(16.1)
Net cash flows from investing activities	(39.1)	(81.9)
CASH FLOWS FROM FINANCING ACTIVITIES		
Issue of share capital under employee share plans	1.2	1.5
New borrowings	15.0	–
Repayment of borrowings	(15.0)	–
Lease liability payments	(4.3)	(5.3)
Dividends paid	(77.5)	(89.1)
Net cash flows from financing activities	(80.6)	(92.9)
Net increase (decrease) in cash	(6.2)	43.3
Opening cash	30.9	36.4
Effect of foreign exchange rates	(0.4)	(0.5)
Closing cash	24.3	79.2
RECONCILIATION OF CLOSING CASH		
Cash and cash equivalents	48.4	93.2
Bank overdrafts	(24.1)	(14.0)
Closing cash	24.3	79.2

	Unaudited 2019 NZ\$M	Unaudited 2020 NZ\$M
CASH FLOW RECONCILIATION		
Profit after tax	121.2	225.5
Add (deduct) non-cash items:		
Depreciation – right-of-use assets	4.7	5.0
Depreciation and amortisation – other assets	23.8	32.0
Share based payments	2.9	3.7
Movement in provisions	(1.4)	7.8
Movement in deferred tax assets / liabilities	(8.4)	(21.4)
Movement in net tax payables	(10.4)	32.0
Foreign currency translation	2.3	(7.4)
Other non-cash items	(2.1)	3.8
	11.4	55.5
Net working capital movements:		
Trade and other receivables	(7.4)	(14.1)
Inventories	(10.2)	(87.1)
Trade and other payables	(1.5)	38.3
	(19.1)	(62.9)
Net cash flows from operating activities	113.5	218.1

The accompanying Notes form an integral part of the Financial Statements.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

For the six months ended 30 September 2020

1. GENERAL INFORMATION

Reporting entity

Fisher & Paykel Healthcare Corporation Limited (the "Company" or "Parent") together with its subsidiaries (the "Group") is a leading designer, manufacturer and marketer of medical device products and systems for use in both hospital and homecare settings. Products are sold in over 120 countries worldwide. The Company is a limited liability company incorporated and domiciled in New Zealand.

Statement of compliance

The Company is registered under the Companies Act 1993 and is an FMC reporting entity under Part 7 of the Financial Markets Conduct Act 2013. The Company is also listed on the New Zealand Stock Exchange (NZX) and the Australian Securities Exchange (ASX).

Basis of preparation

These consolidated financial statements for the six months ended 30 September 2020 have been prepared in accordance with New Zealand Generally Accepted Accounting Practice (NZ GAAP). They comply with New Zealand Equivalent to International Accounting Standard 34: Interim Financial Reporting (NZ IAS 34) and International Accounting Standard 34: Interim Financial Reporting (IAS 34). The Company and Group are designated as profit-oriented entities for financial reporting purposes.

These consolidated financial statements do not include all of the notes normally included in an annual financial report. Accordingly, this report should be read in conjunction with the audited consolidated financial statements for the year ended 31 March 2020.

Presentation currency

These consolidated financial statements are presented in New Zealand dollars (NZD) to the nearest hundred thousand dollars unless otherwise stated.

Accounting policies

All accounting policies have been applied on a basis consistent with those used and described in the audited consolidated financial statements for the year ended 31 March 2020.

2. SIGNIFICANT TRANSACTIONS AND EVENTS FOR THE CURRENT PERIOD

The following significant transactions and events affected the financial performance and financial position of the Group for the six month period ended 30 September 2020:

Share capital

During the six months ended 30 September 2020, the Group issued 1,553,005 shares on exercise of employee share options and performance share rights.

Funding and short-term investments

The Company had total available committed debt funding of NZ\$215 million as at 30 September 2020, of which approximately NZ\$149 million was undrawn. As at 30 September 2020, the weighted average maturity of borrowing facilities was 1.9 years.

As at 30 September 2020, the Group has invested available cash on hand of \$65 million in short-term investments. These investments have maturities between 91 and 122 days with banking institutions that have a long term credit rating of Standard & Poors' A- and above and are invested at average interest rates of 1.2%.

COVID-19

In March 2020, the World Health Organisation declared the outbreak of COVID-19 as a pandemic. Since the outbreak of COVID-19, the Company's focus has been on manufacturing and supplying products that are directly involved in treating patients with COVID-19.

Management have assessed the impact of COVID-19 on all aspects of the balance sheet. Specifically, the carrying value of receivables, inventory and warranty exposure were considered, with provisioning reflecting management's best estimate of the impact based on information available at the time of preparing these financial statements. The carrying value of land held at fair value has been assessed for appropriateness. There has been no material impact on the balance sheet.

As a result of currency volatility during this period, the Group's portfolio of derivatives has changed from being a net liability to a net asset, with the corresponding offset in the cash flow hedge reserve.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

3. OPERATING REVENUE AND SEGMENTAL INFORMATION

	Unaudited 2019 NZ\$M	Unaudited 2020 NZ\$M
For the six months ended 30 September		
Sales Revenue	574.3	910.6
Foreign exchange loss on hedged sales	(3.4)	(0.4)
Total operating revenue	570.9	910.2
Revenue by product group		
Hospital products	353.6	681.0
Homecare products	214.7	226.2
	568.3	907.2
Distributed and other products	2.6	3.0
Total operating revenue	570.9	910.2
Revenue after hedging by geographical location of customer:		
North America	259.6	373.9
Europe	158.3	269.9
Asia Pacific	126.5	184.4
Other	26.5	82.0
Total operating revenue	570.9	910.2

4. OPERATING EXPENSES

	Unaudited 2019 NZ\$M	Unaudited 2020 NZ\$M
For the six months ended 30 September		
Profit before tax includes the following expenses:		
Depreciation - right-of-use assets	4.7	5.0
Depreciation and amortisation - other assets	23.8	32.0
Employee benefits expense	201.7	287.8

5. DERIVATIVE FINANCIAL INSTRUMENTS

Financial instruments are either carried at amortised cost, less any provision for impairment, or fair value. The carrying value of all financial assets and liabilities approximates fair value.

There have been no changes to the Group's hedging policy during the period. The Group enters into foreign currency option contracts or forward foreign currency contracts within policy parameters to manage the net risk associated with anticipated sales or costs. The Group generally applies hedge accounting to all derivative financial instruments.

All derivative financial instruments continue to be re-measured to their fair value. Derivative financial instruments continue to be classified as being within Level 2 of the fair value hierarchy and there were no changes in valuation techniques during the period.

Contractual amounts of derivative financial instruments were as follows:

	Audited 31 March 2020 NZ\$M	Unaudited 30 September 2020 NZ\$M
Foreign currency forward contracts and options		
Sale commitments forward exchange contracts	1,873.2	1,698.4
Purchase commitments forward exchange contracts	86.8	75.6
Foreign currency borrowing forward exchange contracts	16.9	17.7
NZD call option contracts purchased	38.0	19.0
Collar option contracts - NZD call options purchased (i)	70.9	45.9
Collar option contracts - NZD put options sold (i)	76.6	49.2
Interest rate derivatives		
Interest rate swaps	52.1	45.8
Interest rate options	12.5	11.4

(i) Foreign currency contractual amounts of put and call options are equal.

Undiscounted foreign currency contractual amounts for outstanding hedges were as follows:

	Audited 31 March 2020 M	Unaudited 30 September 2020 M
Sale Commitments		
United States dollars	US\$659.3	US\$569.5
European Union euros	€322.3	€295.0
Japanese yen	¥11,075.0	¥9,725.0
Purchase Commitments		
Mexican pesos	MEX\$1,285.5	MEX\$1,146.5

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

6. COMMITMENTS

	Audited 31 March 2020 NZ\$M	Unaudited 30 September 2020 NZ\$M
Capital expenditure commitments contracted for but not recognised as at the reporting date:		
Within one year	31.2	34.1
Between one and two years	0.3	–
Between two and five years	–	–
	31.5	34.1

7. CONTINGENT LIABILITIES

Periodically the Group is party to litigation including product liability and patent claims.

The Directors are unaware of the existence of any claim or contingencies that would have a material impact on the operations of the Group.

8. RELATED PARTY TRANSACTIONS

During the period the Group has not entered into any material contracts involving related parties or directors' interests. No amounts owed by related parties have been written off or forgiven during the period. Apart from directors' fees, key executive remuneration and dividends paid by the Group to its directors as shareholders of the company, there have been no related party transactions.

9. DIVIDENDS

On 26 June 2020 the Directors approved the payment of a fully imputed 2020 final dividend of \$89.1 million (15.5 cents per share) which was paid on 17 July 2020. A supplementary dividend of 2.7353 cents per share was also paid to eligible non-resident shareholders.

Subsequent event – dividend declared

On 24 November 2020 the Directors approved the payment of a fully imputed 2021 interim dividend of \$92.2 million (16 cents per share) to be paid on 16 December 2020. A supplementary dividend of 2.8236 cents per share was also approved for eligible non-resident shareholders.

10. SUBSEQUENT EVENTS

On 14 October 2020 the US\$30 million debt facility, which expired on 1 November 2020, was replaced with two new NZ\$30 million multi-currency facilities expiring 30 September 2025.

There are no other subsequent events other than the dividend as set out in Note 9.



INDEPENDENT REVIEW REPORT REPORT ON THE CONSOLIDATED FINANCIAL STATEMENTS

To the shareholders of Fisher & Paykel Healthcare Corporation Limited

OUR QUALIFIED CONCLUSION

We have reviewed the consolidated financial statements of Fisher & Paykel Healthcare Corporation Limited (the Company) and its subsidiaries (the Group), which comprise the consolidated balance sheet as at 30 September 2020, and the consolidated income statement, the consolidated statement of comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the six month period ended on that date, and significant accounting policies and other explanatory information.

Except for the adjustments to the consolidated financial statements that we might have become aware of had it not been for the situation described in the Basis for qualified conclusion section of our report, based on our review nothing has come to our attention that causes us to believe that the consolidated financial statements of the Group do not present fairly, in all material respects, the financial position of the Group as at 30 September 2020, and its financial performance and its cash flows for the six months ended on that date, in accordance with IAS 34 and NZ IAS 34.

BASIS FOR QUALIFIED CONCLUSION

We conducted our review in accordance with the New Zealand Standard on Review Engagements 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity* (NZ SRE 2410 (Revised)). Our responsibilities are further described in the *Auditor's responsibilities for the review of the financial statements* section of our report.

Due to the COVID-19 pandemic, certain of the Group's annual finished products inventory counts and materials cycle counts planned to be held on or close to 31 March 2020 did not occur. As a result, we did not observe the counting of certain physical inventories at 31 March 2020 and were unable to satisfy ourselves sufficiently by alternative means as to the quantities and condition of inventory held at that date. We consequently qualified our audit opinion on the consolidated financial statements for the year ended 31 March 2020.

Since opening inventories enter into the determination of the financial performance for the current period, our review conclusion is modified as we were unable to determine whether adjustments might have been necessary in respect of the profit for the six months ended 30 September 2020 reported in the consolidated income statement and consolidated statement of comprehensive income, and the possible effect of this matter on the comparability of the current period's balance sheet and the corresponding figures.

We are independent of the Group in accordance with the relevant ethical requirements in New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance with these ethical requirements. In addition to our role as auditor, our firm carries out other services for the Group in the areas of treasury related financial markets risk analysis and commentary, regulatory tax compliance in Mexico and other assurance services in relation to constant currency disclosures. The provision of these other services has not impaired our independence.

DIRECTORS RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The Directors of the Company are responsible on behalf of the Company for the preparation and fair presentation of these consolidated financial statements in accordance with IAS 34 and NZ IAS 34 and for such internal control as the Directors determine is necessary to enable the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

AUDITOR'S RESPONSIBILITY FOR THE REVIEW OF THE FINANCIAL STATEMENTS

Our responsibility is to express a conclusion on the consolidated financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the consolidated financial statements, taken as a whole, are not prepared in all material respects, in accordance with IAS 34 and NZ IAS 34. A review of consolidated financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing and International Standards on Auditing (New Zealand) and consequently does not enable us to obtain assurance that we might identify in an audit. Accordingly, we do not express an audit opinion on these consolidated financial statements.

WHO WE REPORT TO

This report is made solely to the Company's Shareholders, as a body. Our review work has been undertaken so that we might state to the Company's Shareholders those matters which we are required to state to them in our review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Shareholders, as a body, for our review procedures, for this report, or for the conclusion we have formed.

The engagement partner on the review resulting in this independent auditor's review report is Keren Blakey.

For and on behalf of:



Chartered Accountants

24 November 2020

Auckland

Directory

DIRECTORS

Scott St John	Chairman, Non-Executive, Independent
Lewis Gradon	Managing Director and Chief Executive Officer
Michael Daniell	Non-Executive
Pip Greenwood	Non-Executive, Independent
Geraldine McBride	Non-Executive, Independent
Neville Mitchell	Non-Executive, Independent
Donal O'Dwyer	Non-Executive, Independent

EXECUTIVE MANAGEMENT TEAM

Lewis Gradon	Managing Director and Chief Executive Officer
Lyndal York	Chief Financial Officer
Paul Shearer	Senior Vice President – Sales & Marketing
Andrew Somervell	Vice President – Products & Technology
Winston Fong	Vice President – Surgical Technologies
Brian Schultz	Vice President – Quality & Regulatory
Nicola Talbot	Vice President – Human Resources
Nicholas Fourie	Vice President – Information & Communication Technology
Jonti Rhodes	General Manager – Supply Chain
Marcus Driller	Vice President – Corporate

REGISTERED OFFICES

New Zealand:

Physical address: 15 Maurice Paykel Place,
East Tamaki, Auckland 2013,
New Zealand
Telephone: +64 9 574 0100
Postal address: PO Box 14348, Panmure,
Auckland 1741, New Zealand
Website: www.fphcare.com
Email: investor@fphcare.co.nz

Australia:

Physical address: 19-31 King St, Nunawading,
Melbourne, Victoria 3131, Australia
Telephone: +61 3 9871 4900
Postal address: PO Box 159, Mitcham
Victoria 3132, Australia

STOCK EXCHANGES

The Company's ordinary shares are listed on the NZX Main Board and the ASX.

SHARE REGISTRAR

In New Zealand:

Link Market Services Limited

Physical address: Level 11, Deloitte Centre,
80 Queen Street,
Auckland 1010, New Zealand
Postal address: PO Box 91976,
Auckland 1142, New Zealand
Facsimile: +64 9 375 5990
Investor enquiries: +64 9 375 5998
Website: www.linkmarketservices.co.nz
Email: enquiries@linkmarketservices.co.nz

In Australia:

Link Market Services Limited

Physical address: Level 12, 680 George Street,
Sydney, NSW 2000, Australia
Postal address: Locked Bag A14, Sydney South,
NSW 1235, Australia
Facsimile: +61 2 9287 0303
Investor enquiries: +61 2 8280 7111
Internet address: www.linkmarketservices.com.au
Email: registrars@linkmarketservices.com.au

Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in acute and chronic respiratory care, surgery and the treatment of obstructive sleep apnea.



Important notice

Disclaimer

The information in this presentation is for general purposes only and should be read in conjunction with Fisher & Paykel Healthcare Corporation Limited's (FPH) Interim Report 2021 and accompanying market releases. Nothing in this presentation should be construed as an invitation for subscription, purchase or recommendation of securities in FPH.

This presentation includes forward-looking statements about the financial condition, operations and performance of FPH and its subsidiaries. These statements are based on current expectations and assumptions regarding FPH's business and performance, the economy and other circumstances. As with any projection or forecast, the forward-looking statements in this presentation are inherently uncertain and susceptible to changes in circumstances. FPH's actual results may differ materially from those expressed or implied by those forward-looking statements.

Half year business highlights

+ CONTRIBUTED

to the global fight against COVID-19 by increasing manufacturing production on some hospital hardware devices by more than six times.

+ ACCELERATED

the installation of production lines in the Daniell Building, our fourth manufacturing facility in New Zealand.

+ COMMENCED

planning for a third manufacturing facility in Mexico to be completed in financial year 2023.

+ PRESENTED

virtual Nasal High Flow / COVID-19 symposium for 900 attendees at the European Respiratory Society Congress 2020.

+ DEVELOPED

a new education website to provide training and support to clinicians treating patients with COVID-19.

+ APPOINTED

Scott St John as chair of the Board, replacing director Tony Carter, who retired in August.

Impact of COVID-19

- Our people
 - Our people continue to go above and beyond
 - Priority has been ensuring the safety of our people, and therefore protect our ability to manufacture, supply and train end users on essential respiratory support
 - Since January 2020, have hired over 1000 additional direct manufacturing staff in NZ and over 700 additional direct manufacturing staff in Mexico
 - Provided profit sharing bonus of \$12m to recognise the incredible efforts of our people
- Hospital product group
 - H1 FY21 hardware growth of 383% CC
 - Increased output for some of our hospital hardware products by more than six times and doubled output for some of our hospital consumable products since January 2020
 - Brought forward capex spend for new product tooling and manufacturing capacity, including commencing planning for the third manufacturing facility in Mexico


Key half year financial results

H1 FY21 (6 months to 30 September 2020)

	% of Revenue	NZ\$M	ΔPCP^	ΔCC*
Operating revenue	100%	910.2	59%	61%
Hospital operating revenue	75%	681.0	93%	94%
Homecare operating revenue	25%	226.2	5%	6%
Gross margin / Gross profit	62%	561.9	-534bps	-420bps
SG&A	21%	(188.1)	15%	16%
R&D	7%	(64.6)	20%	20%
Total operating expenses	28%	(252.7)	17%	17%
Operating profit	34%	309.2	86%	95%
Profit after tax	25%	225.5	86%	87%

Hospital product group

H1 FY21 HOSPITAL REVENUE COMPOSITION



■ Hardware ■ Consumables

HARDWARE



F&P 950 System



F&P 850 System



F&P AIRVO2



F&P HumiGard

CONSUMABLES



Invasive ventilation



Non-invasive ventilation



Optiflow™ nasal high flow



Surgical



H1 FY20 Hospital revenue composition*
Hardware: 15% Consumables: 85%

*~\$9m has been re-classified from Hospital consumables to Hospital hardware in H1 FY20 to better reflect their nature and usage

Hospital product group

H1 FY21

75% OF OPERATING REVENUE

HOSPITAL OPERATING REVENUE
(H1 FY21 \$681.0M)

NZ\$ ↑ **93%**

CONSTANT CURRENCY ↑ **94%**

NEW APPLICATIONS*
CONSUMABLES REVENUE


NZ\$ ↑ **41%**

CONSTANT CURRENCY ↑ **43%**

- H1 FY21 Hospital hardware growth of 383% in constant currency, with strong demand for our range of humidifiers and Airvos
- Strong customer demand for our Optiflow and Airvo systems, driven by clinical trial results and COVID-19
- New applications consumables* made up 63% of H1 FY21 Hospital consumables revenue, 63% in H1 FY20

Homecare product group

H1 FY21 HOMECARE REVENUE COMPOSITION



■ Hardware ■ Consumables

H1 FY20 Homecare revenue composition
Hardware: 16% Consumables: 84%

HARDWARE



F&P SleepStyle



F&P myAIRVO 2



F&P 810System

CONSUMABLES



CPAP Therapy/OSA



Home Respiratory Support



F&P Vitera



F&P Eson2



F&P Brevida



ersonal use only

Homecare product group

H1 FY21

25% OF OPERATING
REVENUE

HEMOCARE OPERATING REVENUE
(H1 FY21 \$226.2M)

NZ\$ ↑ 5%

CONSTANT
CURRENCY ↑ 6%

MASKS REVENUE


NZ\$ ↑ 3%

CONSTANT
CURRENCY ↑ 3%

- Home Respiratory Support business grew strongly, driven by strong myAirvo sales
- OSA mask revenue impacted by reduced new patient diagnosis due to COVID-19
- Released F&P Evora compact nasal mask in the US, and a patient mask app in the US, Canada, Australia and UK

Gross Margin

GROSS MARGIN




— — — Long Term Gross Margin target

- Gross margin for the half year:
 - decreased by 534 bps to 61.7%
 - decreased by 420 bps in constant currency
 - decrease primarily driven by an increase in freight cost as a result of COVID-19
- Excluding additional freight costs, gross margin was in line with H1 FY20 in constant currency

Note: the long term gross margin target is based on an assumption of a continuation of the current business environment.

Operating Margin

OPERATING (EBIT) MARGIN



— — — Long Term Operating Margin target

Operating expenses

- NZ\$252.7M, +17% (+17% CC)
- Operating margin increased by 489bps (+610bps CC) to 34% due to operating expense growth of 17%, significantly lower than sales growth of 59%

Research & Development expenses

- NZ\$64.6M, +20% (+20% CC)
- Reflecting underlying growth and timing of R&D projects

Selling, General & Administrative expenses

- NZ\$188.1M, +15% (+16% CC)


Note: the long term operating margin target is based on an assumption of a continuation of the current business environment.

Cash Flow and Balance Sheet

	H1 FY20 NZ\$M	H1 FY21 NZ\$M
Operating cash flow	113.5	218.1
Capital expenditure (including purchases of intangible assets)	86.6	94.5
Lease liability payments	4.3	5.3
Free cash flow	22.6	118.3
	FY2020 NZ\$M	H1 FY21 NZ\$M
Net cash (including short-term investments)	42.2	78.1
Total assets	1,435.0	1,631.7
Total equity	973.8	1,223.1
Gearing (debt/debt + equity)*	-4.3%	-7.1%

Gearing and Dividend

- Target gearing ratio* of +5% to -5% debt to debt plus equity
 - Gearing ratio as at 30 September 2020 was -7.1%
- Increased interim dividend by 33%:
 - 16.00 cps + 6.22 cps imputation credit for NZ residents (gross dividend of NZ 22.22 cps)
 - Fully imputed
 - 2.82 cps non-resident supplementary dividend



Foreign exchange effects

- 50% of operating revenue in USD (FY20: 49%) and 18% in € (FY20: 19%).

	Year to 31 March					
Hedging position for our main exposures	FY21	FY22	FY23	FY24	FY25	FY26-27
USD % cover of expected exposure	95%	75%	40%	30%	30%	-
USD average rate of cover	0.654	0.658	0.637	0.630	0.624	-
EUR % cover of expected exposure	95%	70%	55%	35%	35%	5%
EUR average rate of cover	0.554	0.538	0.521	0.509	0.502	0.470


Hedging cover percentages have been rounded to the nearest 5%

Reconciliation of Constant Currency to Actual Income Statements	H1 FY20 NZ\$M	H1 FY21 NZ\$M
Profit after tax (constant currency)	125.4	234.6
Spot exchange rate effect	(3.0)	(4.5)
Foreign exchange hedging result	(2.0)	(1.0)
Balance sheet revaluation	0.8	(3.6)
Profit after tax (as reported)	121.2	225.5

Revenue and expenses by currency


H1 FY21 (for the 6 months ended 30 September 2020)

REVENUE BY CURRENCY




■ NZD ■ USD ■ EUR ■ MXN ■ Other

COST OF SALES BY CURRENCY



■ NZD ■ USD ■ EUR ■ MXN ■ Other

OPERATING EXPENSES BY CURRENCY



■ NZD ■ USD ■ EUR ■ MXN ■ Other

Outlook FY2021

Guide assumptions *(note these are not a forecast or a prediction of the course of COVID-19):*

- Hospital hardware sales return to normal levels from January 2021
- The use of our hospital hardware returns down to approximately normal rates for the second half of the financial year
- OSA diagnosis rates are reduced for the second half of the financial year, due to limited access to customers.
- Freight costs remain elevated, resulting in reduction in gross margin of approximately 200 bps in constant currency for the full financial year compared to the prior financial year.
- Exchange rates of NZD:USD 0.69, NZD:EUR 0.58
- For FY21, based on the assumptions listed above:
 - Operating revenue – approximately NZ\$1.72 billion
 - Net profit after tax – approximately NZ\$400 million to NZ\$415 million
- Capital expenditure expected to be approximately NZ\$185 million
 - Manufacturing capacity and new product tooling brought forward

Overview



Fisher & Paykel Healthcare at a glance

Global leader in respiratory humidification devices

- Medical device manufacturer with leading positions in respiratory care and obstructive sleep apnea
- 50 years' experience in changing clinical practice to solutions that provide better clinical outcomes and improve effectiveness of care
- Estimated NZ\$20+ billion and growing market opportunity driven by demographics
- Significant organic long-term growth opportunities in respiratory care, OSA, COPD and surgery
- Large proportion (68%) of revenue from recurring items, consumables and accessories
- High level of innovation and investment in R&D with strong product pipeline
- High barriers to entry

Global presence



Strong financial performance

- Continued target, and history of, doubling our revenue (in constant currency terms) every 5 to 6 years
- Targeting gross margin of 65% and operating margin of 30%
- Growth company with a strong history of increasing dividend payments

~NZ\$20+ billion and growing market opportunity

Total addressable market estimates

HOSPITAL

~90+ million patients (including ~50+ million in Hospital Respiratory Support)*

Invasive Ventilation



Non-invasive Ventilation



Hospital Respiratory Support



Surgical Humidification



NEW APPLICATIONS

Applications outside of invasive ventilation

HEMOCARE

~100+ million patients


Home Respiratory Support



Obstructive Sleep Apnea



Our aspiration




OUR ASPIRATION:
Sustainably
DOUBLING
our constant
currency revenue
every 5-6 years.

Markets and products

- Hospital
 - Heated humidification
 - Respiratory care
 - Neonatal care
 - Surgery
- Homecare
 - Masks
 - Flow generators
 - Data management tools
 - Respiratory care in the home

Recurring items, consumables and accessories approximately 68% of operating revenue (H1 FY20: 84%)

REVENUE BY PRODUCT GROUP
6 MONTHS TO 30 SEPTEMBER 2020




Impact of changing demographics


- Population age and weight both increasing
 - US population 65 years+ to grow ~80% over next 20 years¹
 - US males 60 - 74 years, average weight increased 0.4 kg/year since 1960²
- 60% of US healthcare cost is after age 65 years³
- Developing markets increasing healthcare spending
 - Total health spending is increasing more rapidly in low and middle income countries (close to 6% on average) than in high income countries (4%)⁴



US POPULATION OVER AGE 65
(MILLIONS)




Hospital cost breakdown



Lower care intensity = lower cost

MEAN ANNUAL COPD-RELATED MEDICAL, PHARMACY
AND TOTAL COSTS BY CARE INTENSITY COHORT




「 Hospital 」



Respiratory humidification


- Normal airway humidification is bypassed or compromised during ventilation or oxygen therapy
- Mucociliary transport system operates less effectively
- Need to deliver gas at physiologically normal levels
 - 37°C body core temperature
 - 44mg/L 100% saturated



Optiflow - displacing conventional oxygen therapy

CONVENTIONAL OXYGEN THERAPY

NON-INVASIVE VENTILATION



Patient groups who may benefit from Optiflow

ADULTS:

- Acute respiratory failure
- Asthma
- Atelectasis
- Bronchiectasis
- Bronchitis
- Burns
- COPD
- Chest trauma
- Emphysema
- Palliative Care
- Pneumonia
- Pulmonary embolism
- Respiratory compromise
- Viral pneumonia
- Carbon monoxide poisoning

PAEDIATRICS/NEONATES:

- Infant respiratory distress
- Bronchiolitis



Clinical outcomes of Optiflow nasal high flow therapy

Optiflow NHF therapy is associated with:

ADULTS:

- REDUCED intubation⁶
- REDUCED re-intubation^{7, 8, 9}
- REDUCED bilevel ventilation⁸
- REDUCED nursing workload⁸
- INCREASED ventilator free days⁶
- IMPROVED comfort & patient tolerance⁷
- IMPROVED compliance⁷
- REDUCED COPD exacerbations¹⁰

PAEDIATRICS:


- REDUCED intubation¹¹
- REDUCED length of stay¹²
- REDUCED respiratory distress¹³

NEONATES:

- NON-INFERIORITY with nasal CPAP¹⁴
- REDUCED nasal trauma^{15, 16}
- REDUCED respiratory distress¹⁷

Optiflow NHF - a growing body of clinical evidence

NASAL HIGH FLOW CLINICAL PAPERS PUBLISHED ANNUALLY



- The publication of 437 clinical papers on NHF continues to signify a high level of clinical interest in the therapy
- Of the 65 controlled studies* on the use of NHF for respiratory support in adults, F&P products have been used in 60

Source: PubMed. Data in years 2000-2018 restated to be consistent with updated PubMed database


* Controlled studies: randomised controlled trials, non-randomised controlled trials and randomised crossover trials

Evidence based COVID-19 guidelines

	No. of studies	Optiflow	Flow rate >45 l/min	Clinical guideline references			
				NIH	ANZICS	SCCM	WHO
Zhao ²¹ 2017	10	100%	90%	●			
OU ²² 2017	5	80%	100%			●	
NI ²³ 2018	8	100%	75%			●	
Rochweg ²⁴ 2019	9	100%	66%	●		●	●
Agarwal ²⁵ 2020	12	92%	66%		●		
Total	22	91%	82%	●	●	●	●

Strong growth in hospital new applications

CONSTANT CURRENCY REVENUE GROWTH RATE
IN NEW APPLICATIONS CONSUMABLES*



- New applications consumables currently make up 63% of Hospital consumables revenue, from 62% in FY19 and 64% in FY20

New applications consumables: Non-invasive ventilation, Optiflow, Airvo, Surgical
* Adjusted to exclude impact of US distribution transition in FY16 and FY17

「 Homecare 」



Obstructive Sleep Apnea

- Temporary closure of airway during sleep
- Can greatly impair quality of sleep, leading to fatigue; also associated with hypertension, stroke and heart attack
- Estimate >100 million people affected in developed countries
- Most common treatment is CPAP (Continuous Positive Airway Pressure)
 - Key issue with CPAP is compliance
 - Humidification provides significant acceptance and compliance improvements



Mask matters most


- Masks are key to compliance
- Unique, patented designs
- Released F&P Evora compact nasal mask in the US, and a patient mask app in the US, Canada, Australia and UK.



F&P EVORA™



F&P VITERA™



F&P BREVIDA™

Home respiratory support

- Chronic obstructive pulmonary disease (COPD) is a lung disease which is commonly associated with smoking
- Emphysema and chronic bronchitis are both forms of COPD
- Chronic respiratory disease, primarily COPD, is the third leading cause of death in the world¹⁷
- 6% of US adults have been diagnosed with COPD¹⁸ (~15 million people)
- 4-10% COPD prevalence worldwide¹⁹ (~400 million people)
- Emerging evidence for COPD patients using NHF at home, reduced exacerbation rates¹⁰, reduced hypercapnia^{27,28}, and improved Quality of life^{10,27}.



High level of innovation and investment in R&D


- R&D represents 7% of operating revenue:^{*} NZ\$64.6M
- Product pipeline includes:
 - Humidifier controllers
 - Masks
 - Respiratory consumables
 - Flow generators
 - Compliance monitoring solutions

330 US patents, 419 US pending,
1378 Rest of world patents,
1264 Rest of world pending[†]



Growing patent portfolio

FISHER & PAYKEL HEALTHCARE US PATENT PORTFOLIO (2008 – 2020)



Average remaining life of FPH patent portfolio (all countries): 11.5 years*

38 * As at 31 March 2020

Manufacturing and operations

Auckland, New Zealand


- Four buildings: 110,000 m² / 1,180,000 ft²
- Co-location of R&D and manufacturing in NZ a competitive advantage

Tijuana, Mexico

- Two buildings: 41,000 m² / 450,000 ft²
- Commenced planning of third manufacturing facility in Tijuana, which is to be commissioned within the next two years.


Manufacturing expansion

- The second Mexico facility, fourth New Zealand facility and the planned new Mexico building, together add an additional 17,000 m² of cleanroom manufacturing space, to a base of 28,400 m² available prior to their construction.



Environmental, Social & Governance

Summary of key environmental metrics



Sustainability disclosures and indices

We participate annually in a suite of well-respected sustainability disclosure programmes and have been included this year in the Dow Jones Sustainability Index and the FTSE4Good index.



CDP (Carbon Disclosure Project) grading

Climate	Supplier engagement	Water
B	B -	C




FTSE4Good

Strong global presence

- Direct/offices
 - Hospitals, home care dealers
 - Sales/support offices in North America, Europe, Asia, South America, Middle East and Australasia, 18 distribution centres
 - ~1,000 employees in 39 countries
 - Ongoing international expansion
- Distributors
 - +150 distributors worldwide
- Original Equipment Manufacturers
 - Supply most leading ventilator manufacturers
- Sell in more than 120 countries in total


REVENUE BY REGION
6 MONTHS TO 30 SEPTEMBER 2020




Ownership structure and listings

- Listed on NZX and ASX (NZX.FPH, ASX.FPH)


SHAREHOLDING STRUCTURE AS AT
30 SEPTEMBER 2020



GEOGRAPHICAL OWNERSHIP AS AT
30 SEPTEMBER 2020



Consistent growth strategy



References

References

1. Clinical guidelines for use of NHF on Covid-19 patients, including those issued by the HHS, WHO, SCCM, ACEP, NIH and the CDC.
2. Grayson K, Vincent, Victoria A, Velkoff. The Next Four Decades. The Older Population in the United States: 2010 to 2050. US Census Bureau, 2010.
3. Cynthia L Ogden, Cheryl D Fryar et al. Mean Body Weight, Height, and Body Mass Index (BMI) 1960-2002. US Centers for Disease Control and Prevention, 2004.
4. Berhanu Alemayehu, Kenneth E Warner. The Lifetime Distribution of Health Care Costs. Health Serv Res. 2004 June; 39(3): 627-642
5. KeX, Agnes S et al. Public Spending on Health: A Closer Look at Global Trends. World Health Organisation 2018.
6. Frat JP, Thille AW, Mercat A et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. *N Engl J Med*. 2015;372(23):2185-96
7. Maggiore SM, Idone FA, Vaschetto R et al. Nasal high-flow versus Venturi mask oxygen therapy after extubation. Effects on oxygenation, comfort, and clinical outcome. *Am J Respir Crit Care Med*. 2014;190(3):282-8
8. Stéphan F, Barrucand B, Petit P et al. High-Flow Nasal Oxygen vs Noninvasive Positive Airway Pressure in Hypoxemic Patients After Cardiothoracic Surgery: A Randomized Clinical Trial. *JAMA*. 2015;313(23):2331-9
9. Hernández G, Vaquero C, González P, et al. Effect of Postextubation High-Flow Nasal Cannula vs Conventional Oxygen Therapy on Reintubation in Low-Risk Patients: A Randomized Clinical Trial. *JAMA*. 2016;315(13):1354-1361. doi:10.1001/jama.2016.2711
10. Storgaard LH, Hockey HU, Laursen BS, Weinreich UM. Long-term effects of oxygen-enriched high-flow nasal cannula treatment in COPD patients with chronic hypoxemic respiratory failure. *Int J Chron Obstruct Pulmon Dis* 2018;16;13:1195-1205
11. Wing R, James C, Maranda LS et al. Use of high-flow nasal cannula support in the emergency department reduces the need for intubation in pediatric acute respiratory insufficiency. *Pediatr Emerg Care*. 2012;28(11):1117-23
12. McKiernan C, Chua LC, Visintainer PF et al. High flow nasal cannulae therapy in infants with bronchiolitis. *J Pediatr*. 2010;156(4):634-8
13. Milési C, Baleine J, Matecki S et al. Is treatment with a high flow nasal cannula effective in acute viral bronchiolitis? A physiologic study. *Intensive Care Med*. 2013 Jun;39(6):1088-94
14. Manley BJ, Owen LS, Doyle LW et al. High-flow nasal cannulae in very preterm infants after extubation. *N Engl J Med*. 2013;369(15):1425-33
15. Yoder BA, Stoddard RA, Li M, King J et al. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. *Pediatrics*. 2013;131(5):e1482-90
16. Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. *J Pediatr*. 2013;162(5):949-54
17. Saslow JG, Aghai ZH, Nakhla TA et al. Work of breathing using high-flow nasal cannula in preterm infants. *J Perinatol*. 2006;26(8):476-80
18. World Health Organisation (2018) The top 10 causes of death, Available at: <https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death> (Accessed: 24 May 2018)
19. Nicole M Kosacz, Antonello Punturieri et al. Chronic Obstructive Pulmonary Disease Among Adults-United States 2011. US Centers for Disease Control and Prevention, 2012.
20. R J Halbert, Sharon Isonaka, Dorothy George, Ahmar Iqbal. Interpreting COPD Prevalence Estimates. *Chest*. 2003; 123:5 1684 – 1692.
21. Zhao H , Wang H, Sun F, et al. High-flow Nasal Cannula Oxygen Therapy Is Superior to Conventional Oxygen Therapy but Not to Noninvasive Mechanical Ventilation on Intubation Rate: A Systematic Review and Meta-Analysis. *Crit Care*. 2017 Jul;21(1):184.
22. Ni YN, Luo J, Yu H, et al. Can High-flow Nasal Cannula Reduce the Rate of Endotracheal Intubation in Adult Patients With Acute Respiratory Failure Compared With Conventional Oxygen Therapy and Noninvasive Positive Pressure Ventilation?: A Systematic Review and Meta-analysis. *Chest*. 2017 Apr;151(4):764-775.
23. Ou X, Hua Y, Liu J, et al. Effect of High-Flow Nasal Cannula Oxygen Therapy in Adults With Acute Hypoxemic Respiratory Failure: A Meta-Analysis of Randomized Controlled Trials. *CMAJ*. 2017 Feb 21;189(7):E260-E267.
24. Rochweg B, Granton D, Wang DX, et al. High Flow Nasal Cannula Compared With Conventional Oxygen Therapy for Acute Hypoxemic Respiratory Failure: A Systematic Review and Meta-Analysis. *Intensive Care Med*. 2019 May;45(5):563-572.
25. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. *Canadian Journal of Anesthesia*. 2020 May; 67(9):1217-1248.

25 November 2020

Results announcement

Results for announcement to the market		
Name of issuer	Fisher & Paykel Healthcare Corporation Limited	
Reporting Period	6 months to 30 September 2020	
Previous Reporting Period	6 months to 30 September 2019	
Currency	NZD	
	Amount (000s)	Percentage change
Revenue from continuing operations	\$910,200	+59%
Total Revenue	\$910,200	+59%
Net profit/(loss) from continuing operations	\$225,500	+86%
Total net profit/(loss)	\$225,500	+86%
Final Dividend		
Amount per Quoted Equity Security	0.16000000 \$/share	
Imputed amount per Quoted Equity Security	0.06222222 \$/share	
Record Date	04 December 2020	
Dividend Payment Date	16 December 2020	
	Current period	Prior comparable period
Net tangible assets per Quoted Equity Security	NZ\$1.87	NZ\$1.40
A brief explanation of any of the figures above necessary to enable the figures to be understood	Not applicable	
Authority for this announcement		
Name of person authorised to make this announcement	Marcus Driller	
Contact person for this announcement	Marcus Driller	
Contact phone number	+64 9 574 0110	
Contact email address	marcus.driller@fphcare.co.nz	
Date of release through MAP	25 November 2020	

Unaudited financial statements accompany this announcement.

25 November 2020
Distribution Notice

Section 1: Issuer information				
Name of issuer	Fisher & Paykel Healthcare Corporation Limited			
Financial product name/description	Interim Dividend			
NZX ticker code	FPH			
ISIN	NZFAPE0001S2			
Type of distribution	Full Year		Quarterly	
	Half Year	X	Special	
	DRP applies			
Record date	04 December 2020			
Ex-Date	03 December 2020			
Payment date	16 December 2020			
Total monies associated with the distribution	\$92,203,502 million based on shares on issue at 24 November 2020 for cash distribution			
Source of distribution	Retained earnings			
Currency	NZD			
Section 2: Distribution amounts per financial product				
Gross distribution	0.22222222 \$/share			
Gross taxable amount	0.22222222 \$/share			
Total cash distribution	0.16000000 \$/share			
Excluded amount	N/A			
Supplementary distribution amount	0.02823529 \$/share			
Section 3: Imputation credits and Resident Withholding Tax				
Is the distribution imputed	Fully imputed			
If fully or partially imputed, please state imputation rate as % applied	100%			
Imputation tax credits per financial product	0.06222222 \$/share			
Resident Withholding Tax per financial product	0.01111111 \$/share			
Section 4: Distribution re-investment plan (if applicable)				
Not applicable				
Section 5: Authority for this announcement				
Name of person authorised to make this announcement	Marcus Driller			
Contact person for this announcement	Marcus Driller			
Contact phone number	+64 9 574 0110			
Contact email address	marcus.driller@fphcare.co.nz			
Date of release through MAP	25 November 2020			